Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network

Authors:

Abstract
No abstract available
Funding Information
  • National Institutes of Health (U10HL069294)
  • Eastern Cooperative Oncology Group (CA180820, CA180853, CA 180799)
  • Southwest Oncology Group NCTN (U10 CA180888)
  • National Heart, Lung and Blood Institute (U10HL069294)
  • National Cancer Institute
  • Alliance for Clinical Trials in Oncology (U10CA180821 and U10CA180882)
  • ECOG-ACRIN Cancer Research Group (CA 180820, CA 180853, CA 180799)
  • Southwest Oncology Group (U10CA180888)

This publication has 40 references indexed in Scilit: